The FDA issued an emergency use authorization (EUA) for Paxlovid (nirmatrelvir tablets and ritonavir tablets co-packaged for oral use) for the treatment of mild-to-moderate COVID-19 in patients who are high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is only available via prescription and should be initiated as soon as possible after diagnosis and within five days of symptom onset. Paxlovid is not a substitute for vaccination.
